The Royal College of Nursing has ended its commercial partnership with Teva UK, removing the pharmaceutical firm as a sponsor for an upcoming event at the union’s London headquarters following pressure from campaign groups over the company’s legal sanctions.
Royal College of Nursing Cuts Ties With Teva UK
The Royal College of Nursing, representing more than 500,000 nurses in the UK, has axed Teva UK as a commercial partner and sponsor of a forthcoming event on migraine and headaches at the union’s London headquarters. In a letter directed to Nurses for Palestine, the chair of the RCN’s ruling council, Carmel O’Boyle, verified this resolution, explaining that extended checks revealed several activities by Teva Pharmaceuticals that faced legal penalties and public scrutiny running contrary to RCN and RCNi principles.
The affected event, the RCNi nursing leadership summit covering migraine and headache services, is scheduled for October 30, 2026. O’Boyle confirmed that the event will go ahead as planned despite the sponsorship change. Teva UK is the British arm of the global drug giant Teva Pharmaceuticals, which stands as one of the NHS’s biggest suppliers of medicines.
Did You Know? Teva has faced substantial financial penalties over the past decade, ordered to pay about £1bn in fines and other payments by the European Commission and US authorities for bribery, price-fixing, and abuse of its market position.
Campaign Groups Pressure Nursing Union to Drop Sponsor
The union’s decision followed sustained pressure from campaign groups Nurses for Palestine and UK Healthcare Petitions to Royal Colleges. Pro-Palestine groups pushing the RCN to drop Teva UK claimed the decision was a major breakthrough for grassroots healthcare organizing and the international boycott, divestment, and sanctions movement aimed at isolating Israel worldwide. A spokesperson for Nurses for Palestine welcomed the move, asserting that Teva has no place sponsoring professional bodies dedicated to healing, care, and preserving human life.
The UKHPRC further remarked that medical associations keeping business ties with enterprises connected to state apparatuses implicated—whether by international authorities or formal findings—in severe breaches of global law, such as genocide, apartheid, and crimes against humanity, remains completely unacceptable. The corporate scrutiny also encompasses substantial regulatory penalties. In 2024, the European Commission fined Teva €462.6m for blocking rival firms from competing with Copaxone across seven European countries. In 2023, Teva agreed with the US Department of Justice to pay $225m in fines as an alternative to prosecution after being charged with fixing the price of three drugs, following a 2016 settlement involving $519m over bribery of government officials in Russia, Ukraine, and Mexico.
Teva Expresses Disappointment over Politicization of Healthcare
Teva expressed disappointment over the RCN’s decision and argued that healthcare had been politicized. A Teva spokesperson stated that as one of the largest suppliers of medicines to the UK, the company valued its longstanding partnership with the RCN and the opportunity to support healthcare professionals and patients. The firm noted it is seeking further dialogue with the organization, maintaining that healthcare is at its best when focused on patients rather than politics.
Activists supporting Palestine are currently urging the Royal College of Pharmacy to sever ties with Teva UK by removing them as a sponsor for their upcoming annual conference next month and revoking the exhibition booth the company has reserved, all stemming from the nursing union’s recent verdict.
What are the wider implications for UK pharmaceutical supply chains?
Frequently Asked Questions
Which specific event was affected by the decision?
The RCNi nursing leadership summit on migraine and headache services, scheduled for October 30, 2026, at the union’s London headquarters, was stripped of Teva UK’s sponsorship.
What specific regulatory fines has Teva faced in recent years?
Teva was fined €462.6m by the European Commission in 2024 for blocking rival firms from competing with its multiple sclerosis treatment Copaxone, and agreed to pay $225m in 2023 to the US Department of Justice over price-fixing charges.
Which organizations are currently targeting other medical bodies?
Pro-Palestine campaigners, including groups such as Nurses for Palestine and UK Healthcare Petitions to Royal Colleges, are actively lobbying other professional institutions like the Royal College of Pharmacy.
How will the RCN handle future commercial partnerships?
Chair of the RCN ruling council Carmel O’Boyle stated that the organization is taking action through enhanced due diligence to ensure future commercial relationships align strictly with the values of the nursing profession.
How do you view the balance between corporate sponsorship in healthcare and political or ethical considerations raised by professional unions?